PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

Market Cap $103.1M Add to my watchlist

Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PAR	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/20	618.72KB	Share
PAR	Paradigm presents MPS VI poster at WORLD Symposium	PRICE SENSITIVE	13/02/20	127.6KB	Share
PAR	Cleansing Notice and Appendix 2A		10/02/20	377.6KB	Share
PAR	Cleansing Notice and Appendix 2A		03/02/20	377.67KB	Share
PAR	Quarterly Update and Appendix 4C - quarterly	PRICE SENSITIVE	31/01/20	231.02KB	Share
PAR	Updated Appendix 2A		15/01/20	253.04KB	Share
PAR	Cleansing Notice		14/01/20	148.97KB	Share
PAR	Appendix 2A		14/01/20	252.93KB	Share
PAR	Cleansing Notice and Appendix 3B	PRICE SENSITIVE	18/12/19	690.74KB	Share
PAR	Cleansing Notice and Appendix 3B		13/12/19	404.6KB	Share
PAR	Paradigm End of Calendar Year Update	PRICE SENSITIVE	12/12/19	109.38KB	Share
PAR	Cleansing Notice		04/12/19	205.37KB	Share
PAR	Appendix 3B		04/12/19	426.46KB	Share
PAR	Cleansing Notice and Appendix 3B		25/11/19	397.52KB	Share
PAR	Change of Director's Interest Notice		19/11/19	176.76KB	Share
PAR	Change in substantial holding		14/11/19	193.39KB	Share
PAR	Change of Director's Interest Notice		14/11/19	161.28KB	Share
PAR	Cleansing Notice and Appendix 3B		11/11/19	396.78KB	Share
PAR	Results of Meeting		07/11/19	201.62KB	Share
PAR	Paradigm AGM Presentation	PRICE SENSITIVE	07/11/19	1.05MB	Share
PAR	Quarterly Update and Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	350.45KB	Share
PAR	PARADIGM PROVIDES REGULATORY FILING UPDATE	PRICE SENSITIVE	25/10/19	212.17KB	Share
PAR	Cleansing Notice and Appendix 3B		22/10/19	1.01MB	Share
PAR	Notice of Annual General Meeting/Proxy Form		04/10/19	376.19KB	Share
PAR	Cleansing Notice and Appendix 3B		01/10/19	854.94KB	Share
PAR	Osteoarthritis pain reduced by Paradigms Zilosul (PPS)	PRICE SENSITIVE	30/09/19	371.09KB	Share
PAR	Cleansing Notice and Appendix 3B		24/09/19	397.03KB	Share
PAR	Cleansing Notice and Appendix 3B		17/09/19	1.01MB	Share
PAR	Cleansing Notice and Appendix 3B		12/09/19	396.59KB	Share
PAR	PAR Expanded Access IND Cleared by US FDA	PRICE SENSITIVE	10/09/19	232.16KB	Share
PAR	Appendix 4G and 2019 Corporate Governance Statement		30/08/19	403.85KB	Share
PAR	Appendix 4E and 2019 Annual Report	PRICE SENSITIVE	30/08/19	1.12MB	Share
PAR	PARs drug reduces cartilage degradation in subjects with OA	PRICE SENSITIVE	29/08/19	1.19MB	Share
PAR	PARADIGM FILES FIRST IND WITH US FDA	PRICE SENSITIVE	07/08/19	146.39KB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	134.51KB	Share
PAR	Response to ASX Appendix 3Y Query		05/07/19	522.29KB	Share
PAR	Change of Director's Interest Notice		03/07/19	176.53KB	Share
PAR	Change in substantial holding		02/07/19	382.01KB	Share
PAR	Change of Director's Interest Notice		02/07/19	430.5KB	Share
PAR	Paradigm EOFY Update	PRICE SENSITIVE	28/06/19	326.67KB	Share
PAR	PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL	PRICE SENSITIVE	04/06/19	408.29KB	Share
PAR	PAR reports consistent pain reduction in knee OA of patients	PRICE SENSITIVE	28/05/19	352.81KB	Share
PAR	PAR CORRECTS AFR ARTICLE	PRICE SENSITIVE	21/05/19	83.76KB	Share
PAR	Updated Appendix 3B		13/05/19	428.13KB	Share
PAR	Appendix 3B		13/05/19	425.63KB	Share
PAR	Successful Completion of Retail Entitlement Offer	PRICE SENSITIVE	09/05/19	142.58KB	Share
PAR	Paradigm Corporate Update - May 2019	PRICE SENSITIVE	08/05/19	301.29KB	Share
PAR	Quarterly Report and Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	1.22MB	Share
PAR	Appendix 3B		26/04/19	279.04KB	Share
PAR	Cleansing Notice under section708A		26/04/19	404.13KB	Share
PAR	Completion of Institutional Entitlement Offer	PRICE SENSITIVE	24/04/19	161.84KB	Share
PAR	Cleansing statement under Section 708AA		24/04/19	156.1KB	Share
PAR	Change of Director's Interest Notice		23/04/19	474.6KB	Share
PAR	PAR Accelerated Non-Renounceable Rights Issue Offer Booklet	PRICE SENSITIVE	17/04/19	589.83KB	Share
PAR	Paradigm Confirms Capital Raise Commitments	PRICE SENSITIVE	17/04/19	104.96KB	Share
PAR	PARADIGM UPDATED CORPORATE PRESENTATION	PRICE SENSITIVE	15/04/19	1.93MB	Share
PAR	Appendix 3B		15/04/19	762.82KB	Share
PAR	PARADIGM LAUNCHES A$77.9M CAPITAL RAISE	PRICE SENSITIVE	15/04/19	100.11KB	Share
PAR	Cleansing statement under Section 708AA		15/04/19	223.23KB	Share
PAR	Trading Halt	PRICE SENSITIVE	15/04/19	463.2KB	Share
PAR	PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET	PRICE SENSITIVE	15/04/19	4.01MB	Share
PAR	Trading Halt	PRICE SENSITIVE	11/04/19	511.1KB	Share
PAR	Response to ASX Price Query	PRICE SENSITIVE	28/03/19	675.46KB	Share
PAR	Paradigm (PAR) Updated Investor Presentation	PRICE SENSITIVE	13/03/19	19.1MB	Share
PAR	Change of Director's Interest Notice		08/03/19	473.03KB	Share
PAR	S&P DJI Announces March 2019 Quarterly Rebalance	PRICE SENSITIVE	08/03/19	175.31KB	Share
PAR	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/19	384.01KB	Share
PAR	Cleansing Notice and Appendix 3B		14/02/19	953.72KB	Share
PAR	PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES	PRICE SENSITIVE	14/02/19	1.85MB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	423.18KB	Share
PAR	PARADIGMS SUPPLEMENTARY PHASE 2B DATA	PRICE SENSITIVE	20/12/18	812.37KB	Share
PAR	PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS	PRICE SENSITIVE	18/12/18	3.09MB	Share
PAR	PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL	PRICE SENSITIVE	18/12/18	576.83KB	Share
PAR	PAR - Conference Call Details - Phase 2b OA Results		17/12/18	176.21KB	Share
PAR	Trading Halt	PRICE SENSITIVE	14/12/18	505.17KB	Share
PAR	Change in substantial holding		13/12/18	154.21KB	Share
PAR	Change of Director's Interest Notice		13/12/18	430.61KB	Share
PAR	Appendix 3B and Cleansing Notice		13/12/18	952.71KB	Share
PAR	PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION	PRICE SENSITIVE	07/12/18	140.04KB	Share
PAR	Cleansing Notice and Appendix 3B		30/11/18	953.33KB	Share
PAR	Cleansing Notice and Appendix 3B		27/11/18	954.06KB	Share
PAR	Results of Meeting		26/11/18	118.78KB	Share
PAR	Paradigm's AGM Presentation	PRICE SENSITIVE	26/11/18	1.13MB	Share
PAR	Paradigm in-licenses treatment for rare joint disease	PRICE SENSITIVE	22/11/18	115.87KB	Share
PAR	PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND	PRICE SENSITIVE	15/11/18	277.14KB	Share
PAR	PAR reports pain reduction in 145 people with osteoarthritis	PRICE SENSITIVE	07/11/18	333.11KB	Share
PAR	Cleansing Notice and Appendix 3B		01/11/18	954.01KB	Share
PAR	Quarterly Report and Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	376.54KB	Share
PAR	Notice of Annual General Meeting/Proxy Form		26/10/18	510.97KB	Share
PAR	Paradigm Agreement With USA Past Players Network	PRICE SENSITIVE	25/10/18	357.94KB	Share
PAR	Paradigm's Updated Corporate Presentation	PRICE SENSITIVE	25/10/18	1.62MB	Share
PAR	Paradigm Raises A$9 Million	PRICE SENSITIVE	25/10/18	368.92KB	Share
PAR	Trading Halt	PRICE SENSITIVE	23/10/18	442.11KB	Share
PAR	PAR REPORTS PAIN REDUCTION IN OA PATIENTS	PRICE SENSITIVE	25/09/18	467.25KB	Share
PAR	Phase2a RossRiver Virus Clinical Trial Recruitment Finalised	PRICE SENSITIVE	28/08/18	258.57KB	Share
PAR	Appendix 4G and Corporate Governance Statement		24/08/18	157.27KB	Share
PAR	Appendix 4E and 2018 Annual Report	PRICE SENSITIVE	24/08/18	582.45KB	Share
PAR	PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN	PRICE SENSITIVE	15/08/18	334.37KB	Share
PAR	Cleansing Notice and Appendix 3B		08/08/18	964.42KB	Share
PAR	PAR achieves 100 per cent recruitment in Phase 2b OA Trial	PRICE SENSITIVE	06/08/18	334.6KB	Share

PAR Half Yearly Report and Accounts
14/02/20	PRICE SENSITIVE	618.72KB	Share
PAR Paradigm presents MPS VI poster at WORLD Symposium
13/02/20	PRICE SENSITIVE	127.6KB	Share
PAR Cleansing Notice and Appendix 2A
10/02/20		377.6KB	Share
PAR Cleansing Notice and Appendix 2A
03/02/20		377.67KB	Share
PAR Quarterly Update and Appendix 4C - quarterly
31/01/20	PRICE SENSITIVE	231.02KB	Share
PAR Updated Appendix 2A
15/01/20		253.04KB	Share
PAR Cleansing Notice
14/01/20		148.97KB	Share
PAR Appendix 2A
14/01/20		252.93KB	Share
PAR Cleansing Notice and Appendix 3B
18/12/19	PRICE SENSITIVE	690.74KB	Share
PAR Cleansing Notice and Appendix 3B
13/12/19		404.6KB	Share
PAR Paradigm End of Calendar Year Update
12/12/19	PRICE SENSITIVE	109.38KB	Share
PAR Cleansing Notice
04/12/19		205.37KB	Share
PAR Appendix 3B
04/12/19		426.46KB	Share
PAR Cleansing Notice and Appendix 3B
25/11/19		397.52KB	Share
PAR Change of Director's Interest Notice
19/11/19		176.76KB	Share
PAR Change in substantial holding
14/11/19		193.39KB	Share
PAR Change of Director's Interest Notice
14/11/19		161.28KB	Share
PAR Cleansing Notice and Appendix 3B
11/11/19		396.78KB	Share
PAR Results of Meeting
07/11/19		201.62KB	Share
PAR Paradigm AGM Presentation
07/11/19	PRICE SENSITIVE	1.05MB	Share
PAR Quarterly Update and Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	350.45KB	Share
PAR PARADIGM PROVIDES REGULATORY FILING UPDATE
25/10/19	PRICE SENSITIVE	212.17KB	Share
PAR Cleansing Notice and Appendix 3B
22/10/19		1.01MB	Share
PAR Notice of Annual General Meeting/Proxy Form
04/10/19		376.19KB	Share
PAR Cleansing Notice and Appendix 3B
01/10/19		854.94KB	Share
PAR Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
30/09/19	PRICE SENSITIVE	371.09KB	Share
PAR Cleansing Notice and Appendix 3B
24/09/19		397.03KB	Share
PAR Cleansing Notice and Appendix 3B
17/09/19		1.01MB	Share
PAR Cleansing Notice and Appendix 3B
12/09/19		396.59KB	Share
PAR PAR Expanded Access IND Cleared by US FDA
10/09/19	PRICE SENSITIVE	232.16KB	Share
PAR Appendix 4G and 2019 Corporate Governance Statement
30/08/19		403.85KB	Share
PAR Appendix 4E and 2019 Annual Report
30/08/19	PRICE SENSITIVE	1.12MB	Share
PAR PARs drug reduces cartilage degradation in subjects with OA
29/08/19	PRICE SENSITIVE	1.19MB	Share
PAR PARADIGM FILES FIRST IND WITH US FDA
07/08/19	PRICE SENSITIVE	146.39KB	Share
PAR Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	134.51KB	Share
PAR Response to ASX Appendix 3Y Query
05/07/19		522.29KB	Share
PAR Change of Director's Interest Notice
03/07/19		176.53KB	Share
PAR Change in substantial holding
02/07/19		382.01KB	Share
PAR Change of Director's Interest Notice
02/07/19		430.5KB	Share
PAR Paradigm EOFY Update
28/06/19	PRICE SENSITIVE	326.67KB	Share
PAR PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL
04/06/19	PRICE SENSITIVE	408.29KB	Share
PAR PAR reports consistent pain reduction in knee OA of patients
28/05/19	PRICE SENSITIVE	352.81KB	Share
PAR PAR CORRECTS AFR ARTICLE
21/05/19	PRICE SENSITIVE	83.76KB	Share
PAR Updated Appendix 3B
13/05/19		428.13KB	Share
PAR Appendix 3B
13/05/19		425.63KB	Share
PAR Successful Completion of Retail Entitlement Offer
09/05/19	PRICE SENSITIVE	142.58KB	Share
PAR Paradigm Corporate Update - May 2019
08/05/19	PRICE SENSITIVE	301.29KB	Share
PAR Quarterly Report and Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	1.22MB	Share
PAR Appendix 3B
26/04/19		279.04KB	Share
PAR Cleansing Notice under section708A
26/04/19		404.13KB	Share
PAR Completion of Institutional Entitlement Offer
24/04/19	PRICE SENSITIVE	161.84KB	Share
PAR Cleansing statement under Section 708AA
24/04/19		156.1KB	Share
PAR Change of Director's Interest Notice
23/04/19		474.6KB	Share
PAR PAR Accelerated Non-Renounceable Rights Issue Offer Booklet
17/04/19	PRICE SENSITIVE	589.83KB	Share
PAR Paradigm Confirms Capital Raise Commitments
17/04/19	PRICE SENSITIVE	104.96KB	Share
PAR PARADIGM UPDATED CORPORATE PRESENTATION
15/04/19	PRICE SENSITIVE	1.93MB	Share
PAR Appendix 3B
15/04/19		762.82KB	Share
PAR PARADIGM LAUNCHES A$77.9M CAPITAL RAISE
15/04/19	PRICE SENSITIVE	100.11KB	Share
PAR Cleansing statement under Section 708AA
15/04/19		223.23KB	Share
PAR Trading Halt
15/04/19	PRICE SENSITIVE	463.2KB	Share
PAR PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET
15/04/19	PRICE SENSITIVE	4.01MB	Share
PAR Trading Halt
11/04/19	PRICE SENSITIVE	511.1KB	Share
PAR Response to ASX Price Query
28/03/19	PRICE SENSITIVE	675.46KB	Share
PAR Paradigm (PAR) Updated Investor Presentation
13/03/19	PRICE SENSITIVE	19.1MB	Share
PAR Change of Director's Interest Notice
08/03/19		473.03KB	Share
PAR S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19	PRICE SENSITIVE	175.31KB	Share
PAR Half Yearly Report and Accounts
21/02/19	PRICE SENSITIVE	384.01KB	Share
PAR Cleansing Notice and Appendix 3B
14/02/19		953.72KB	Share
PAR PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES
14/02/19	PRICE SENSITIVE	1.85MB	Share
PAR Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	423.18KB	Share
PAR PARADIGMS SUPPLEMENTARY PHASE 2B DATA
20/12/18	PRICE SENSITIVE	812.37KB	Share
PAR PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS
18/12/18	PRICE SENSITIVE	3.09MB	Share
PAR PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL
18/12/18	PRICE SENSITIVE	576.83KB	Share
PAR PAR - Conference Call Details - Phase 2b OA Results
17/12/18		176.21KB	Share
PAR Trading Halt
14/12/18	PRICE SENSITIVE	505.17KB	Share
PAR Change in substantial holding
13/12/18		154.21KB	Share
PAR Change of Director's Interest Notice
13/12/18		430.61KB	Share
PAR Appendix 3B and Cleansing Notice
13/12/18		952.71KB	Share
PAR PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION
07/12/18	PRICE SENSITIVE	140.04KB	Share
PAR Cleansing Notice and Appendix 3B
30/11/18		953.33KB	Share
PAR Cleansing Notice and Appendix 3B
27/11/18		954.06KB	Share
PAR Results of Meeting
26/11/18		118.78KB	Share
PAR Paradigm's AGM Presentation
26/11/18	PRICE SENSITIVE	1.13MB	Share
PAR Paradigm in-licenses treatment for rare joint disease
22/11/18	PRICE SENSITIVE	115.87KB	Share
PAR PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND
15/11/18	PRICE SENSITIVE	277.14KB	Share
PAR PAR reports pain reduction in 145 people with osteoarthritis
07/11/18	PRICE SENSITIVE	333.11KB	Share
PAR Cleansing Notice and Appendix 3B
01/11/18		954.01KB	Share
PAR Quarterly Report and Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	376.54KB	Share
PAR Notice of Annual General Meeting/Proxy Form
26/10/18		510.97KB	Share
PAR Paradigm Agreement With USA Past Players Network
25/10/18	PRICE SENSITIVE	357.94KB	Share
PAR Paradigm's Updated Corporate Presentation
25/10/18	PRICE SENSITIVE	1.62MB	Share
PAR Paradigm Raises A$9 Million
25/10/18	PRICE SENSITIVE	368.92KB	Share
PAR Trading Halt
23/10/18	PRICE SENSITIVE	442.11KB	Share
PAR PAR REPORTS PAIN REDUCTION IN OA PATIENTS
25/09/18	PRICE SENSITIVE	467.25KB	Share
PAR Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
28/08/18	PRICE SENSITIVE	258.57KB	Share
PAR Appendix 4G and Corporate Governance Statement
24/08/18		157.27KB	Share
PAR Appendix 4E and 2018 Annual Report
24/08/18	PRICE SENSITIVE	582.45KB	Share
PAR PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN
15/08/18	PRICE SENSITIVE	334.37KB	Share
PAR Cleansing Notice and Appendix 3B
08/08/18		964.42KB	Share
PAR PAR achieves 100 per cent recruitment in Phase 2b OA Trial
06/08/18	PRICE SENSITIVE	334.6KB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 29.8¢		Change 0.003(0.85%)		Mkt cap ! $103.1M

Open	High	Low	Value	Volume
30.0¢	30.0¢	29.5¢	$20.58K	69.07K

Buyers (Bids)

No.	Vol.	Price($)
6	50607	29.5¢

Sellers (Offers)

Price($)	Vol.	No.
30.0¢	13762	6

View Market Depth

No.	Vol.	Price($)
6	50607	0.295
7	37149	0.290
5	61933	0.285
4	108745	0.280
3	13893	0.275

Price($)	Vol.	No.
0.300	13762	6
0.305	30425	5
0.310	32207	3
0.315	59184	6
0.320	122010	6

Last trade - 14.50pm 22/07/2024 (20 minute delay)


Last 29.8¢		Change 0.003 ( 0.85 %)
Open	High	Low	Volume
30.0¢	30.0¢	29.5¢	17880
Last updated 14.25pm 22/07/2024 ?

PAR (ASX) Chart

PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available